1. Introduction

• 1.1 Report Overview and Scope

• 1.2 Market Definition

• 1.3 Study Assumptions and Limitations

• 1.4 Research Methodology

• 1.4.1 Primary Research Approach

• 1.4.2 Secondary Research Approach

• 1.4.3 Data Triangulation and Validation

• 1.5 List of Abbreviations and Acronyms

2. Executive Summary

• 2.1 Market Snapshot and Key Highlights

• 2.2 Key Market Findings and Strategic Insights

• 2.3 Market Attractiveness Analysis by Segment

• 2.4 Analyst Recommendations

3. Market Overview

• 3.1 Definition and Introduction to Nuclear Medicine

• 3.2 Market Taxonomy and Scope

• 3.3 Historical Market Evolution (2021–2025)

• 3.4 Nuclear Medicine Ecosystem Overview

• 3.4.1 Radioisotope Production: Reactor-Based vs. Accelerator/Cyclotron-Based Methods

• 3.4.2 Radiopharmaceutical Manufacturing, Regulatory Compliance, and Cold Chain Logistics

• 3.4.3 Diagnostic Nuclear Medicine: SPECT and PET Imaging Pathways

• 3.4.4 Therapeutic Nuclear Medicine: Radioligand Therapy (RLT) and Targeted Radionuclide Therapy (TRT)

• 3.4.5 Theranostics: Convergence of Diagnostics and Therapeutics in a Single Clinical Pathway

• 3.5 Value Chain Analysis

• 3.5.1 Radioisotope Production (Reactor Facilities, Cyclotrons, Linear Accelerators)

• 3.5.2 Radiopharmaceutical Formulation and Drug Manufacturing

• 3.5.3 Sterilization, Quality Control, and Compliance Services

• 3.5.4 Distributors, Radiopharmacies, and Group Purchasing Organizations (GPOs)

• 3.5.5 End Users (Hospitals, Diagnostic Centers, Specialty Clinics, Research Institutes)

• 3.6 Regulatory and Policy Framework

• 3.6.1 U.S. FDA Regulatory Framework: Title 21 CFR Part 315 & 361, NRC Authorization

• 3.6.2 EMA Centralized Procedure and European Pharmacopoeia Standards for Radiopharmaceuticals

• 3.6.3 IAEA Standards for Radiopharmaceutical Production and Radiation Safety

• 3.6.4 CMS Reimbursement Policies: Pass-Through Payments and Tc-99m Non-HEU Add-On Payments

• 3.6.5 Asia-Pacific Regulatory Developments (PMDA, NMPA, CDSCO)

• 3.7 Macroeconomic Factors Influencing Market Growth

• 3.7.1 Rising Global Burden of Cancer, Cardiovascular, and Neurological Diseases

• 3.7.2 Healthcare Infrastructure Expansion in Emerging Markets

• 3.7.3 Radioisotope Supply Chain Vulnerabilities and Mo-99 Production Diversification Initiatives

• 3.7.4 Strategic Investment in Radiopharmaceutical Manufacturing Capacity (Novartis, GE HealthCare, Lantheus)

4. Market Dynamics

• 4.1 Key Market Drivers

• 4.1.1 Rising Prevalence of Cancer: 20 Million New Cases Globally in 2022 (WHO)

• 4.1.2 Growing FDA Approvals of Radiopharmaceutical Therapeutics (Pluvicto, Lutathera, Xofigo)

• 4.1.3 Rapid Expansion of Theranostics in Precision Oncology (PSMA, DOTATATE Platforms)

• 4.1.4 Accelerating Adoption of PET/CT and SPECT/CT Hybrid Imaging Technologies

• 4.1.5 Rising Demand for Targeted Radionuclide Therapy in Prostate, NETs, and Thyroid Cancers

• 4.1.6 Favorable Reimbursement Reforms and Government Investment in Mo-99 Non-HEU Production

• 4.1.7 Expanding Applications in Neurology (Dementia, Parkinson's, Alzheimer's Disease Imaging)

• 4.2 Market Restraints

• 4.2.1 Lack of Adequate Reimbursement for Diagnostic Radiopharmaceuticals in Key Markets

• 4.2.2 Complex Cold Chain Logistics and Short Half-Life of Radioisotopes Limiting Distribution

• 4.2.3 High Cost of Advanced Radiopharmaceutical Therapies Limiting Patient Access

• 4.2.4 Radiation Safety Concerns and Stringent Regulatory Compliance Burdens

• 4.3 Market Opportunities

• 4.3.1 AI-Driven Dosimetry, Imaging Analysis, and Radiopharmaceutical Trial Discovery Platforms (SNMMI Global Trial Finder)

• 4.3.2 Next-Generation Alpha-Emitter Therapies: Actinium-225 (Ac-225), Bismuth-213, Terbium-149

• 4.3.3 Expanding Copper-Based Radiopharmaceuticals: 64Cu-SARTATE, 68Cu-Based PET Tracers

• 4.3.4 Geographic Expansion into Underserved Markets: Southeast Asia, Africa, and Latin America

• 4.3.5 Partnerships Between Pharma Giants and Isotope Producers to Secure Long-Term Supply (ITM–Alpha-9, Sanofi–Orano Med)

• 4.4 Market Challenges

• 4.4.1 Shortage of Skilled Nuclear Medicine Technologists and Specialist Physicians

• 4.4.2 Limited Number of High-Flux Research Reactors for Mo-99 and Ac-225 Production

• 4.4.3 Geopolitical Risks to Radioisotope Supply Chains (Russia–Ukraine Impact on ROSATOM Supply)

• 4.4.4 Standardization Gaps in Radiopharmaceutical Dosimetry Across International Clinical Guidelines

5. Porter's Five Forces Analysis

• 5.1 Bargaining Power of Suppliers (Reactor Operators, Cyclotron Facilities, API Manufacturers)

• 5.2 Bargaining Power of Buyers (Hospital Systems, GPOs, Government Health Agencies)

• 5.3 Threat of New Entrants

• 5.4 Threat of Substitutes (Conventional Chemotherapy, MRI, CT, Non-Radioactive Targeted Therapy)

• 5.5 Intensity of Competitive Rivalry

6. PESTEL Analysis

• 6.1 Political Factors

• 6.2 Economic Factors

• 6.3 Social Factors

• 6.4 Technological Factors

• 6.5 Environmental Factors

• 6.6 Legal Factors

7. Technology and Innovation Landscape

• 7.1 SPECT Imaging Technologies: Tc-99m, Tl-201, Ga-67, I-123, and Advanced SPECT/CT Systems

• 7.2 PET Imaging Technologies: F-18 FDG, 68Ga, 68Cu, 11C, and Novel PET/MRI Hybrid Systems

• 7.3 Radioligand Therapy (RLT): Lu-177 PSMA (Pluvicto), Lu-177 DOTATATE (Lutathera) Platforms

• 7.4 Alpha-Emitter Therapy: Ra-223 (Xofigo), Ac-225, Bi-213, Tb-149 Development Pipeline

• 7.5 Beta-Emitter Therapy: I-131, Y-90 (SIR-Spheres, TheraSpheres), Sm-153, Re-186, Lu-177

• 7.6 Brachytherapy: Cs-131, I-125, Pd-103, Ir-192 Isotope Systems

• 7.7 Diffusing Alpha-Emitters Radiation Therapy (DaRT) for Glioblastoma and Solid Tumors

• 7.8 AI-Powered Quantitative Imaging, Dosimetry Software, and Workflow Automation

• 7.9 Companion Diagnostics Paired with Radioligand Therapies (PSMA-PET + Pluvicto, DOTATATE + Lutathera)

• 7.10 Non-HEU Mo-99 Production Technologies (NorthStar Medical Radioisotopes Electron Accelerator Approach)

• 7.11 Digital Nuclear Medicine Platforms and AI-Enabled Nuclear Medicine Theranostic Workflows

8. Market Segmentation Analysis

8.1 By Type

• 8.1.1 Diagnostics

• SPECT Radiopharmaceuticals

• Technetium-99m (Tc-99m) – Dominant SPECT Radiotracer

• Iodine-123 (I-123)

• Thallium-201 (Tl-201)

• Gallium-67 (Ga-67)

• Xenon-133 (Xe-133)

• Others

• PET Radiopharmaceuticals

• Fluorine-18 FDG (FDG-PET/18F) – Dominant PET Tracer

• Gallium-68 (68Ga)

• Copper-64 (68Cu)

• Carbon-11 (11C)

• PYLARIFY (Piflufolastat F-18)

• Illuccix (Gallium Ga-68 Gozetotide)

• Others

• 8.1.2 Therapeutics

• Alpha Emitters (Ra-223, Ac-225, Others)

• Beta Emitters (I-131, Y-90, Sm-153, Re-186, Lu-177, Others)

• Brachytherapy (Cs-131, I-125, Pd-103, Ir-192, Others)

8.2 By Application

• 8.2.1 Oncology (Largest Application: Prostate Cancer, NETs, Thyroid Cancer, Lymphoma)

• 8.2.2 Cardiology (SPECT, PET Myocardial Perfusion Imaging, Therapeutic Applications)

• 8.2.3 Neurology (Alzheimer's Disease, Parkinson's Disease, Epilepsy, Dementia Imaging)

• 8.2.4 Thyroid (SPECT, Therapeutic I-131 Applications)

• 8.2.5 Urology (Prostate Cancer: Dominant Sub-Segment at 22.62% Share in 2024)

• 8.2.6 Pulmonary Scans

• 8.2.7 Endocrine Tumors (DOTATATE-PET, Lu-177 Edotreotide)

• 8.2.8 Bone Metastasis (SPECT, Xofigo / Ra-223 Therapeutic Applications)

• 8.2.9 Lymphoma

• 8.2.10 Others

8.3 By End User

• 8.3.1 Hospitals and Clinics (Dominant: 55.0% Share in 2024)

• 8.3.2 Diagnostic Imaging Centers

• 8.3.3 Others (Research Institutes, Academic Medical Centers, Specialty Theranostics Centers)

9. Regional Market Analysis

9.1 North America

• 9.1.1 Market Overview and Growth Outlook (Dominant Region: 42.87% Share in 2024)

• 9.1.2 United States (USD 6.81 Billion in 2026; ~49.64% of Global Market)

• 9.1.3 Canada (Nordion – Leading Mo-99 and Co-60 Supplier)

9.2 Europe

• 9.2.1 Market Overview and Regulatory Context (EMA, EURATOM, European Pharmacopoeia)

• 9.2.2 Germany (Dominant Country in Europe; Bayer AG, Eckert & Ziegler Headquarters)

• 9.2.3 United Kingdom

• 9.2.4 France (Curium, Orano Med – Alpha-Emitter RLT Focus)

• 9.2.5 Italy (Bracco Imaging, Advanced Accelerator Applications)

• 9.2.6 Spain

• 9.2.7 Scandinavia (Denmark, Sweden, Norway)

• 9.2.8 Rest of Europe

9.3 Asia-Pacific

• 9.3.1 Market Overview (Third-Largest Region; USD 2.23 Billion in 2026)

• 9.3.2 China (USD 0.94 Billion in 2026; Healthy China 2030 Nuclear Medicine Expansion)

• 9.3.3 Japan (PMDA Approval Pathway; USD 0.75 Billion in 2026; CHD Imaging Demand)

• 9.3.4 India (USD 0.28 Billion in 2026; CDSCO; Jubilant Pharmova Radiopharmacy Network)

• 9.3.5 Australia (ANSTO: World-Leading Mo-99 Producer via OPAL Reactor)

• 9.3.6 South Korea (DuchemBio Nuclear Medicine Leadership)

• 9.3.7 Southeast Asia

• 9.3.8 Rest of Asia-Pacific

9.4 Latin America

• 9.4.1 Market Overview (USD 0.69 Billion in 2026)

• 9.4.2 Brazil (Dominant Country; CNEN Radioisotope Production)

• 9.4.3 Mexico

• 9.4.4 Rest of Latin America

9.5 Middle East and Africa (MEA)

• 9.5.1 Market Overview (GCC: USD 0.31 Billion in 2026)

• 9.5.2 Saudi Arabia

• 9.5.3 United Arab Emirates

• 9.5.4 South Africa (NTP Radioisotopes, SAFARI-1 Reactor; USD 0.06 Billion in 2026)

• 9.5.5 Kuwait

• 9.5.6 Rest of Middle East and Africa

10. Competitive Landscape

• 10.1 Market Concentration and Competitive Overview (Semi-Fragmented Structure)

• 10.2 Market Share Analysis of Top Players (2025)

• 10.3 Competitive Benchmarking Matrix

• 10.4 Key Strategic Developments

• 10.4.1 Mergers and Acquisitions (BMS–RayzeBio USD 4.1 Billion; Life Healthcare–TheraMed; SHINE–Lantheus SPECT Business; Cardinal Health–12 U.S. Radiopharmacies)

• 10.4.2 New Product Approvals and Pipeline Milestones (Pluvicto Earlier-Line Approval March 2025; 177Lu-PNT2002 Phase 3 SPLASH; Lantheus ANDA for 177Lu-Dotatate March 2026)

• 10.4.3 Research Partnerships and Clinical Trial Collaborations (Jubilant–Evergreen Theragnostics; ITM–Alpha-9 Ac-225 Supply; Sanofi–Orano Med Lead-212 RLT Partnership)

• 10.4.4 Manufacturing Capacity Expansion (Novartis 4th U.S. RLT Facility Winter Park FL; Curium–Nucleis PET Acquisition; GE HealthCare Theranostics Platform)

• 10.5 Innovation and R&D Pipeline Analysis

• 10.5.1 Late-Stage Therapeutic Pipeline (Betalutin, Omburtamab, PNT2003, 177Lu-PNT2002, 177Lu-Edotreotide)

• 10.5.2 Alpha Therapy Emerging Pipeline (VMT-α-NET, Actimab-A, ATNM-400, 64Cu-SARTATE)

• 10.6 Patent Landscape and Intellectual Property Trends

• 10.7 Vertical Integration Trends in the Radiopharmaceutical Supply Chain

• 10.8 ESG and Radiation Safety Sustainability Practices in Nuclear Medicine Operations

11. Company Profiles

(The final report includes a complete list of companies)

11.1 GE HealthCare Technologies Inc.

• 11.1.1 Company Overview

• 11.1.2 Financial Performance

• 11.1.3 Product Portfolio

• 11.1.4 Strategic Initiatives

• 11.1.5 SWOT Analysis

11.2 Novartis AG (Advanced Accelerator Applications)

11.3 Lantheus Holdings, Inc.

11.4 Curium Pharma

11.5 Bayer AG

11.6 Siemens Healthineers AG

11.7 Bracco Imaging S.p.A.

11.8 Cardinal Health, Inc.

11.9 Nordion Inc. (Sotera Health)

11.10 Jubilant Pharmova Limited (Jubilant Radiopharma)

11.11 Eckert & Ziegler SE

11.12 NTP Radioisotopes SOC Ltd.

11.13 SHINE Technologies, LLC

11.14 Perspective Therapeutics, Inc.

11.15 ITM Isotope Technologies Munich SE

12. Investment and Opportunity Analysis

• 12.1 High-Growth Segments and Investment Hotspots (Alpha-Emitter RLT, Theranostics, AI-Imaging)

• 12.2 Venture Capital and Private Equity Activity in Radiopharmaceutical Development

• 12.3 Government and Institutional Research Funding (DOE Isotope Program, NIH NCI, BARDA, Horizon Europe)

• 12.4 Emerging Business Models: Vertical Integration, Licensing, Isotope Supply Agreements, and CDMO Partnerships

• 12.5 Strategic Recommendations for Market Stakeholders

13. Impact Analysis

• 13.1 Impact of FDA Approvals of Pluvicto and Lutathera on Radioligand Therapy Market Expansion

• 13.2 Impact of COVID-19 on Nuclear Medicine Procedure Volumes and Supply Chain Recovery

• 13.3 Impact of Radioisotope Supply Chain Disruptions (Mo-99, Ac-225 Shortage) on Market Access

• 13.4 Impact of AI and Digital Pathology on Nuclear Medicine Diagnostic Workflows

• 13.5 Impact of Geopolitical Tensions (Russia–Ukraine, ROSATOM Sanctions) on Global Isotope Supply

14. Appendix

• 14.1 List of Tables

• 14.2 List of Figures

• 14.3 Research Methodology Overview

• 14.4 Data Sources and References

• 14.5 Glossary of Key Terms (RLT, SPECT, PET, DaRT, PSMA, DOTATATE, Mo-99, HEU, ANDA, BLA, GPO, CDMO, etc.)

• 14.6 About the Publisher

15. Disclaimer